---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037360"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2026-08-12T20:15:20+00:00"
generated_at: "2026-08-12T20:16:10.760446+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interpace Q2 2026: revenue $9.1M, income $0.3M vs prior loss; thyroid revenue +9% YoY

## Summary
- Q2 revenue $9.1M, up 9% Pro Forma (ex-PancraGEN); income from continuing ops $0.3M vs $0.5M loss prior year.
- Thyroid revenue +9% YoY, volume +6%; TTM thyroid revenue $36.1M, up 11%; gross margin 62% vs 54% Pro Forma.
- Adjusted EBITDA $0.7M (8% margin) vs $0.2M Pro Forma prior year; includes $0.2M one-time strategic fees.
- H1 2026 income $1.1M vs $0.2M loss Pro Forma; Adjusted EBITDA $2.3M (13% margin); debt-free balance sheet.
- Adding Chief Scientific Officer Sept 8, 2026; pancreatic cancer program in development, no revenue expected in 2026.

## SEC filing metadata
- accession: 0001493152-26-037360
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2026-08-12T20:15:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315226037360/0001493152-26-037360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315226037360/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037360
- JSON: https://secwatch.observer/filing/0001493152-26-037360.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037360.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.